View Item 

Show simple item record

Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
dc.contributor.authorSavarese, Gianluigi
dc.contributor.authorCarrero, Juan‐jesus
dc.contributor.authorPitt, Bertram
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorRosano, Giuseppe M.C.
dc.contributor.authorDahlström, Ulf
dc.contributor.authorLund, Lars H.
dc.date.accessioned2018-11-20T15:35:42Z
dc.date.available2019-11-01T15:10:33Zen
dc.date.issued2018-09
dc.identifier.citationSavarese, Gianluigi; Carrero, Juan‐jesus ; Pitt, Bertram; Anker, Stefan D.; Rosano, Giuseppe M.C.; Dahlström, Ulf ; Lund, Lars H. (2018). "Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry." European Journal of Heart Failure 20(9): 1326-1334.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/146476
dc.publisherJohn Wiley & Sons, Ltd
dc.subject.otherHyperkalaemia
dc.subject.otherMineralocorticoid receptor antagonists
dc.subject.otherGuidelines
dc.subject.otherHeart failure with reduced ejection fraction
dc.titleFactors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146476/1/ejhf1182.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146476/2/ejhf1182_am.pdf
dc.identifier.doi10.1002/ejhf.1182
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceMaggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESCâ HF Pilot). Eur J Heart Fail 2010; 12: 1076 â 1084.
dc.identifier.citedreferenceZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASISâ HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11 â 21.
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709 â 717.
dc.identifier.citedreferencePonikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalezâ Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891 â 975.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137 â e161.
dc.identifier.citedreferenceAlbert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658 â 1665.
dc.identifier.citedreferenceThorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidenceâ based therapy and survival in heart failure in Sweden 2003â 2012. Eur J Heart Fail 2016; 18: 503 â 511.
dc.identifier.citedreferenceFerreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ter Maaten J, Metra M, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors A, Zannad F. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTATâ CHF. Eur J Heart Fail 2017; 19: 1284 â 1293.
dc.identifier.citedreferenceLachaine J, Beauchemin C, Ramos E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol 2011; 11: 4.
dc.identifier.citedreferenceRossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASISâ HF). Circ Heart Fail 2014; 7: 51 â 58.
dc.identifier.citedreferenceVardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypoâ and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014; 7: 573 â 539.
dc.identifier.citedreferenceJonsson A, Edner M, Alehagen U, Dahlstrom U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010; 12: 25 â 31.
dc.identifier.citedreferenceLudvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
dc.identifier.citedreferenceFonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail 2008; 1: 98 â 106.
dc.identifier.citedreferenceNieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopezâ Sendon JL, Ponikowski P, Tavazzi L; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725 â 2736.
dc.identifier.citedreferenceCrespoâ Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlstrom U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Longâ Term Registry (ESCâ HFâ LT): 1â year followâ up outcomes and differences across regions. Eur J Heart Fail 2016; 18: 613 â 625.
dc.identifier.citedreferenceFerreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F. Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? Eur J Heart Fail 2017; 19: 974 â 986.
dc.identifier.citedreferenceEschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASISâ HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASISâ HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585 â 1593.
dc.identifier.citedreferenceLund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson A, Jernberg T, Dahlstrom U. Association between enrolment in a heart failure quality registry and subsequent mortality â a nationwide cohort study. Eur J Heart Fail 2017; 19: 1107 â 1116.
dc.identifier.citedreferenceLund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socioâ economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail 2017; 19: 1270 â 1279.
dc.identifier.citedreferenceLund LH, Svennblad B, Melhus H, Hallberg P, Dahlstrom U, Edner M. Association of spironolactone use with allâ cause mortality in heart failure: a propensity scored cohort study. Circ Heart Fail 2013; 6: 174 â 183.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1182.pdf
Size:
1022.KB
Format:
PDF
View/Open
Name:
ejhf1182_am.pdf
Size:
910.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.